{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:44:41Z","timestamp":1777340681023,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403585"],"award-info":[{"award-number":["82403585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44653-8","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:26:11Z","timestamp":1773653171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti\u2013PD-1 efficacy in bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Chi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guineng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"issue":"3","key":"44653_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"issue":"3","key":"44653_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171 (3), 540\u2013556e25 (2017).","journal-title":"Cell"},{"issue":"7","key":"44653_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.urolonc.2020.01.019","volume":"40","author":"LF Cooley","year":"2022","unstructured":"Cooley, L. F., Glaser, A. P. & Meeks, J. J. Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer. Urologic Oncology: Seminars Original Investigations. 40 (7), 279\u2013286 (2022).","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"3","key":"44653_CR4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/curroncol29030117","volume":"29","author":"IA Voutsadakis","year":"2022","unstructured":"Voutsadakis, I. A. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Curr. Oncol. 29 (3), 1390\u20131407 (2022).","journal-title":"Curr. Oncol."},{"issue":"3","key":"44653_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell 137 (3), 413\u2013431 (2009).","journal-title":"Cell"},{"issue":"3","key":"44653_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 25 (3), 304\u2013317 (2014).","journal-title":"Cancer Cell."},{"issue":"1","key":"44653_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl, G. et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242 (1), 113\u2013125 (2017).","journal-title":"J. Pathol."},{"issue":"6","key":"44653_CR8","doi-asserted-by":"publisher","first-page":"102445","DOI":"10.1016\/j.clgc.2025.102445","volume":"23","author":"A Soliman","year":"2025","unstructured":"Soliman, A. et al. A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. Clin. Genitourin. Cancer. 23 (6), 102445 (2025).","journal-title":"Clin. Genitourin. Cancer"},{"key":"44653_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010131","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran, A. et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel) 13, 131 (2021).","journal-title":"Cancers (Basel)"},{"key":"44653_CR10","doi-asserted-by":"publisher","first-page":"1591379","DOI":"10.3389\/fimmu.2025.1591379","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review. Front. Immunol. 16, 1591379 (2025).","journal-title":"Front. Immunol."},{"issue":"6","key":"44653_CR11","first-page":"e40031","volume":"15","author":"TJ Okobi","year":"2023","unstructured":"Okobi, T. J. et al. Immune checkpoint inhibitors as a treatment option for bladder cancer: Current evidence. Cureus 15(6), e40031 (2023).","journal-title":"Cureus"},{"issue":"1","key":"44653_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41467-025-56462-0","volume":"16","author":"LM Boll","year":"2025","unstructured":"Boll, L. M. et al. Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nat. Commun. 16 (1), 1213 (2025).","journal-title":"Nat. Commun."},{"issue":"12","key":"44653_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00262-025-04224-8","volume":"74","author":"M V\u00e1radi","year":"2025","unstructured":"V\u00e1radi, M. et al. Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma. Cancer Immunol. Immunother. 74 (12), 370 (2025).","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"44653_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.molcel.2014.04.024","volume":"54","author":"G Zhou","year":"2014","unstructured":"Zhou, G. et al. Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Mol. Cell. 54 (6), 960\u2013974 (2014).","journal-title":"Mol. Cell"},{"key":"44653_CR15","doi-asserted-by":"crossref","unstructured":"Vladimir, J. N. B., et al., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med., 8(3), 282\u2013288 (2002).","DOI":"10.1038\/nm0302-282"},{"issue":"6","key":"44653_CR16","doi-asserted-by":"publisher","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","volume":"6","author":"N Mohell","year":"2015","unstructured":"Mohell, N. et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 6(6), e1794 (2015).","journal-title":"Cell Death Dis."},{"issue":"6","key":"44653_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41419-024-06830-3","volume":"15","author":"O Michaeli","year":"2024","unstructured":"Michaeli, O. et al. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy. Cell Death Dis. 15(6), 426 (2024).","journal-title":"Cell Death Dis."},{"issue":"4","key":"44653_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","volume":"30","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death Differ. 30(4), 1033\u20131046 (2023).","journal-title":"Cell Death Differ."},{"issue":"7545","key":"44653_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (7545), 57\u201362 (2015).","journal-title":"Nature"},{"issue":"5","key":"44653_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell, H. N., Stockwell, B. R. & Zou, W. Ironing out the role of ferroptosis in immunity. Immunity 57 (5), 941\u2013956 (2024).","journal-title":"Immunity"},{"issue":"1","key":"44653_CR21","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki, B. et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13 (1), 3676 (2022).","journal-title":"Nat. Commun."},{"key":"44653_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cytogfr.2025.06.007","volume":"84","author":"J Gao","year":"2025","unstructured":"Gao, J. et al. Ferroptosis in immune cells: Implications for tumor immunity and cancer therapy. Cytokine Growth Factor Rev. 84, 59\u201373 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"44653_CR23","doi-asserted-by":"publisher","first-page":"155747","DOI":"10.1016\/j.metabol.2023.155747","volume":"151","author":"R Shah","year":"2024","unstructured":"Shah, R. et al. The role of ROS in tumor infiltrating immune cells and cancer immunotherapy. Metabolism 151, 155747 (2024).","journal-title":"Metabolism"},{"key":"44653_CR24","doi-asserted-by":"publisher","first-page":"1322746","DOI":"10.3389\/fimmu.2023.1322746","volume":"14","author":"L Xiao","year":"2023","unstructured":"Xiao, L. et al. Lipid peroxidation of immune cells in cancer. Front. Immunol. 14, 1322746 (2023).","journal-title":"Front. Immunol."},{"issue":"20","key":"44653_CR25","doi-asserted-by":"publisher","first-page":"eadl0479","DOI":"10.1126\/sciadv.adl0479","volume":"10","author":"X Li","year":"2024","unstructured":"Li, X. et al. Precise modulation and use of reactive oxygen species for immunotherapy. Sci. Adv. 10 (20), eadl0479 (2024).","journal-title":"Sci. Adv."},{"issue":"29","key":"44653_CR26","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","volume":"30","author":"S Lehmann","year":"2012","unstructured":"Lehmann, S. et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 30 (29), 3633\u20133639 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"44653_CR27","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.esmoop.2022.100573","volume":"7","author":"H Park","year":"2022","unstructured":"Park, H. et al. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open 7(5), 100573 (2022).","journal-title":"ESMO Open"},{"key":"44653_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212387","author":"S Ju","year":"2024","unstructured":"Ju, S. et al. Oxidative stress and cancer therapy: Controlling cancer cells using reactive oxygen species. Int. J. Mol. Sci. 25, 12387 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"44653_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171 (2), 273\u2013285 (2017).","journal-title":"Cell"},{"issue":"8","key":"44653_CR30","doi-asserted-by":"publisher","first-page":"12902","DOI":"10.18632\/oncotarget.14186","volume":"8","author":"L Li","year":"2017","unstructured":"Li, L. et al. Reactive oxygen species mediate heat stress-induced apoptosis via ERK dephosphorylation and Bcl-2 ubiquitination in human umbilical vein endothelial cells. Oncotarget 8 (8), 12902\u201312916 (2017).","journal-title":"Oncotarget"},{"issue":"D1","key":"44653_CR31","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M. et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53 (D1), D672\u2013d677 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"44653_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin. Cancer Res. 26 (2), 487\u2013504 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"44653_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","volume":"74","author":"Y Tian","year":"2025","unstructured":"Tian, Y. et al. CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunol. Immunother. 74(2), 55 (2025).","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"44653_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41467-025-68018-3","volume":"17","author":"L Gorline","year":"2025","unstructured":"Gorline, L. et al. Intratumoral delivery of FLT3L with CXCR3\/CCR5 ligands promotes XCR1\u2009+\u2009cDC1 infiltration and activates anti-tumor immunity. Nat. Commun. 17 (1), 1258 (2025).","journal-title":"Nat. Commun."},{"issue":"1","key":"44653_CR35","doi-asserted-by":"publisher","first-page":"12671","DOI":"10.1038\/s41598-018-31048-7","volume":"8","author":"L Haffo","year":"2018","unstructured":"Haffo, L. et al. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Sci. Rep. 8 (1), 12671 (2018).","journal-title":"Sci. Rep."},{"key":"44653_CR36","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202301999","author":"J Michels","year":"2023","unstructured":"Michels, J. et al. APR-246 increases tumor antigenicity independent of p53. Life Sci. Alliance 7(1), e202301999\u00a0(2023).","journal-title":"Life Sci. Alliance"},{"issue":"37","key":"44653_CR37","doi-asserted-by":"publisher","first-page":"eabm9427","DOI":"10.1126\/sciadv.abm9427","volume":"8","author":"KM Fujihara","year":"2022","unstructured":"Fujihara, K. M. et al. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci. Adv. 8 (37), eabm9427 (2022).","journal-title":"Sci. Adv."},{"key":"44653_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071748","author":"A Kotsafti","year":"2020","unstructured":"Kotsafti, A. et al. Reactive oxygen species and antitumor immunity-from surveillance to evasion. Cancers (Basel) 12(7),1748\u00a0(2020).","journal-title":"Cancers (Basel)"},{"issue":"10","key":"44653_CR39","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R. et al. CD8(+) T cells in the cancer-immunity cycle. Immunity 56 (10), 2231\u20132253 (2023).","journal-title":"Immunity"},{"issue":"2","key":"44653_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.molcel.2022.12.023","volume":"83","author":"M Ghosh","year":"2023","unstructured":"Ghosh, M. et al. p53 engages the cGAS\/STING cytosolic DNA sensing pathway for tumor suppression. Mol. Cell 83(2), 266-280.e6 (2023).","journal-title":"Mol. Cell"},{"issue":"6948","key":"44653_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature01850","volume":"424","author":"A Takaoka","year":"2003","unstructured":"Takaoka, A. et al. Integration of interferon-\u03b1\/\u03b2 signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (6948), 516\u2013523 (2003).","journal-title":"Nature"},{"key":"44653_CR42","doi-asserted-by":"publisher","unstructured":"Shah, R. et al. The role of ROS in tumor infiltrating immune cells and cancer immunotherapy. Metabolism, 151 https:\/\/doi.org\/10.1016\/j.metabol.2023.155747 (2024).","DOI":"10.1016\/j.metabol.2023.155747"},{"issue":"1","key":"44653_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-026-01780-z","volume":"19","author":"J Li","year":"2026","unstructured":"Li, J. et al. The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications. J. Hematol. Oncol. 19 (1), 16 (2026).","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"44653_CR44","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1002\/mco2.519","volume":"5","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. Roles of reactive oxygen species in inflammation and cancer. MedComm 5 (4), e519 (2024).","journal-title":"MedComm"},{"issue":"11","key":"44653_CR45","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl. J. Med. 376 (11), 1015\u20131026 (2017).","journal-title":"N Engl. J. Med."},{"issue":"10122","key":"44653_CR46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391 (10122), 748\u2013757 (2018).","journal-title":"Lancet"},{"issue":"7693","key":"44653_CR47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554 (7693), 544\u2013548 (2018).","journal-title":"Nature"},{"issue":"11","key":"44653_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s13238-021-00841-y","volume":"12","author":"G Lei","year":"2021","unstructured":"Lei, G. et al. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell 12(11), 836\u2013857 (2021).","journal-title":"Protein Cell"},{"issue":"12","key":"44653_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang, X. et al. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discov. 9 (12), 1673\u20131685 (2019).","journal-title":"Cancer Discov."},{"issue":"6","key":"44653_CR50","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50(6), 1498-1512e5 (2019).","journal-title":"Immunity"},{"issue":"5","key":"44653_CR51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-\u03baB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 18(5), 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"44653_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euros.2022.06.007","volume":"43","author":"M Besan\u00e7on","year":"2022","unstructured":"Besan\u00e7on, M. et al. Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. Eur. Urol. Open. Sci. 43, 35\u201344 (2022).","journal-title":"Eur. Urol. Open. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44653-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44653-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44653-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:02:28Z","timestamp":1777338148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44653-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44653"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44653-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13595"}}